| Literature DB >> 29983806 |
Alhussain Alzahrani1, Abdulrahman Abdullah Alghamdi1, Rahaf Waggass1.
Abstract
INTRODUCTION: Vici syndrome, a rare autosomal recessive disorder, was first described in 1988 by Vici et al. Only 78 cases have been reported to date. The syndrome is characterised by agenesis of the corpus callosum, hypopigmentation, cardiomyopathy, progressive failure to thrive, dysmorphic features, immunodeficiency and cataracts. Mutations in the gene epg5 have been identified as the cause of Vici syndrome. CASE DESCRIPTION: The parents are a consanguineous Saudi couple with two other children diagnosed with Gaucher disease. The patient was born at term and in the first 5 months had many hospital admissions for a recurrent chest infection. Physical examination, investigations and imaging studies revealed that the patient had agenesis of the corpus callosum, cataracts, psychomotor delay, immunodeficiency and hypopigmentation. The initial echocardiogram was normal. At 7 months, genetic testing confirmed the diagnosis of Vici syndrome with a c.3693G>Ap (Gln1231Gln) mutation in the gene EPG5. The patient developed a chest infection and was admitted to the pediatric intensive care unit. An echocardiogram was repeated and showed significant left ventricular dilation with a Z-score of 3.1, moderate mitral and tricuspid regurgitation, and depressed ventricular function with a fractional shortening of 17% and ejection fraction 37%. The patient's condition deteriorated, and he died aged 8 months.Entities:
Keywords: Cardiomyopathy; EPG5 gene; Vici syndrome
Year: 2018 PMID: 29983806 PMCID: PMC6026433 DOI: 10.3889/oamjms.2018.271
Source DB: PubMed Journal: Open Access Maced J Med Sci ISSN: 1857-9655
Figure 1Brain MRI at age 6 months. Medline sagittal T1 weighted sequence (A), showing agenesis of corpus callosum and hypoplastic pons. Coronal T1 (B) and axial T2 (C) showing loss of white matter and dilated ventricular system
Summary of reported patients with Vici syndrome
| Authors, year | Sex | Age (m) | Clinical outcome |
|---|---|---|---|
| Vici et al., 1988 [ | M | 24 | Deceased |
| M | 36 | ||
| Del Campo et al., 1999 [ | M | 24 | Deceased |
| F | 11 | Deceased | |
| M | 36 | Alive | |
| F | 16 | Deceased | |
| Chiyonobu et al., 2002 [ | F | 19 | Deceased |
| M | 6 | Alive | |
| Miyata et al., 2007 [ | F | 12 | Deceased |
| M | 11 | Alive | |
| McClelland et al., 2010 [ | M | 3 | Deceased |
| Al-Owain et al., 2010 [ | M | 9 | Deceased |
| Rogers et al., 2011 [ | M | 96 | Deceased |
| F | 96 | Deceased | |
| Said et al., 2012 [ | F | 15 | Deceased |
| Finocchi et al., 2012 [ | M | 24 | Alive |
| Özkale et al., 2012 [ | F | 6 | Deceased |
| Cullup et al., 2013 [ | F | 15 | Deceased |
| M | 3 | Alive | |
| M | 48 | Alive | |
| M | 36 | Alive | |
| M | 9 | Alive | |
| M | 36 | Alive | |
| M | 24 | Alive | |
| M | 24 | Alive | |
| F | 120 | Alive | |
| Ehmke et al., 2014 [ | M | 3.5 | Deceased |
| Filloux et al., 2014 [ | F | 17 | Alive |
| Tasdemir et al., 2015 [ | M | 9 | Deceased |
| M | 8 | ||
| El-Kersh et al., 2015 [ | F | 72 | Deceased |
| Byrne et al., 2016 [ | NS | NS | NS |
| Huenerberg et al., 2016 [ | F | 11 | Deceased |
| F | 13 | ||
| Maillard et al., 2017 [ | F | 24 | Alive |
| Hori et al., 2017 [ | F | 84 | Alive |
| F | 24 | Alive | |
| F | 180 | Alive | |
| F | 12 | Deceased | |
| F | 48 | Alive | |
| F | 24 | Alive | |
| M | 168 | Deceased | |
| M | 60 | Alive | |
| M | 84 | Alive | |
| Hedberg-Oldfors et al., 2017 [ | M | 8 | Deceased |
| Elsayed et al., 2018 [ | M | 7 | Deceased |
| M | 8 | Deceased |
M = male; F = female; NS = not specified; m months.
Common clinical features of 78 cases of Vici syndrome
| Feature | Positive | Negative | Not reported | n (%) |
|---|---|---|---|---|
| Recurrent infections | 77 | - | 1 | 77/78 (98.7) |
| Corpus callosum agenesis | 76 | - | 2 | 76/78 (97.4) |
| Profound developmental delay | 76 | 1 | 1 | 76/78 (97.4) |
| Cutaneous manifestations | 75 | 3 | - | 75/78 (96.2) |
| Immune system involvement | 60 | 16 | 2 | 60/78 (76.9) |
| Cardiomyopathy | 51 | 18 | 9 | 51/78 (65.4) |
| Cataract | 49 | 25 | 4 | 49/78 (62.8) |
| Microcephaly | 45 | 15 | 18 | 45/78 (57.7) |
| Hypotonia | 37 | - | 41 | 37/78 (47.4) |
| Seizures | 26 | 16 | 36 | 26/78 (33.3) |
| Growth retardation | 24 | - | 54 | 24/78 (30.8) |